Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, announces receipt of the CE Mark for the Company's patented MEDIHONEY® HCS (hydrogel colloidal sheet) dressings. With this determination the entire current line of MEDIHONEY products has CE marking.
"We will launch commercial sales of MEDIHONEY HCS dressings in Europe in January 2013," said Edward J. Quilty, chief executive officer of Derma Sciences. "This will be a significant launch as it will help bring our products more deeply into the acute care segment and, for the first time, into the burn care segment. Currently approximately 20% of MEDIHONEY product sales are from Europe and we look forward to further penetration of that market with our advanced wound care products."
Derma Sciences' HCS dressings (XTRASORB® and now MEDIHONEY) are differentiated in the market in that they utilize super-absorbing hydrogels not only to provide moisture to dry wounds, but also to absorb moderate to even heavy amounts of wound fluid. This creates extremely versatile dressings that can be used on multiple wound indications and conditions, are easy to use and can be left on wounds for extended periods of time, helping to reduce the overall cost of care. Notably, these novel super-absorbent hydrogels have been shown to lock damaging wound proteases into the dressings, which helps to maintain a more optimal wound environment for healing.
MEDIHONEY is a unique line of patented wound care dressings containing Active Leptospermum Honey from New Zealand, which possess unique qualities that make them ideal for the management of chronic and acute wounds and burns. With a strong and growing base of peer-reviewed evidence including several large-scale randomized controlled studies, MEDIHONEY dressings have shown to be effective for debridement and helping to advance hard-to-heal stalled wounds through the healing process.